View all news

    Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus

    06/26/2020
    Download(opens in new window)PDF 189 KB

    Multimedia Files:

    View all news
    Questions? Please contact us:
    1-800-950-5089 investor-relations@its.jnj.com